XOMA Corporation
Index- P/E52.47 EPS (ttm)0.32 Insider Own0.20% Shs Outstand11.42M Perf Week-5.56%
Market Cap185.30M Forward P/E- EPS next Y-0.31 Insider Trans134.44% Shs Float11.38M Perf Month-5.08%
Income9.70M PEG2.76 EPS next Q-0.23 Inst Own58.60% Short Float3.20% Perf Quarter-18.27%
Sales41.00M P/S4.52 EPS this Y-16.60% Inst Trans-2.86% Short Ratio7.01 Perf Half Y-38.67%
Book/sh11.81 P/B1.44 EPS next Y73.90% ROA6.40% Target Price62.50 Perf Year-31.42%
Cash/sh7.68 P/C2.21 EPS next 5Y19.00% ROE7.40% 52W Range15.68 - 32.08 Perf YTD-18.47%
Dividend- P/FCF8.35 EPS past 5Y15.70% ROI12.10% 52W High-47.17% Beta0.95
Dividend %- Quick Ratio10.40 Sales past 5Y47.00% Gross Margin- 52W Low8.10% ATR1.20
Employees12 Current Ratio10.40 Sales Q/Q11.10% Oper. Margin49.10% RSI (14)42.73 Volatility6.71% 7.18%
OptionableYes Debt/Eq0.00 EPS Q/Q-69.00% Profit Margin23.70% Rel Volume0.70 Prev Close17.00
ShortableYes LT Debt/Eq0.00 EarningsAug 04 BMO Payout0.00% Avg Volume51.92K Price16.95
Recom2.30 SMA20-4.83% SMA50-15.43% SMA200-20.87% Volume33,146 Change-0.29%
Sep-07-21Downgrade Wedbush Outperform → Neutral $22
Jun-29-21Initiated Aegis Capital Buy $60
Jan-19-21Reiterated H.C. Wainwright Buy $30 → $56
Jan-18-18Reiterated H.C. Wainwright Buy $38 → $49
Oct-17-17Resumed H.C. Wainwright Buy $38
Sep-05-17Upgrade Wedbush Neutral → Outperform $9 → $19
Jun-12-17Initiated H.C. Wainwright Buy $15
Nov-14-16Downgrade Wedbush Outperform → Neutral $17 → $14
Mar-11-16Reiterated Wedbush Outperform $6 → $3
Jul-23-15Downgrade Jefferies Buy → Hold
Jul-22-15Downgrade Piper Jaffray Overweight → Neutral
Jul-22-15Downgrade Ladenburg Thalmann Buy → Neutral
Oct-10-14Resumed ROTH Capital Buy $9
Apr-29-14Upgrade MLV & Co Hold → Buy $7
Mar-11-14Downgrade MLV & Co Buy → Hold $8 → $7
Mar-05-14Reiterated Ladenburg Thalmann Buy $6.50 → $10
Oct-31-13Reiterated MLV & Co Buy $7.50 → $8
May-09-13Reiterated Ladenburg Thalmann Buy $5 → $6
May-14-12Initiated Cowen & Co Outperform
Mar-31-11Reiterated MLV Capital Buy $12 → $10
Sep-21-22 07:30AM
Sep-07-22 07:30AM
Sep-01-22 06:20AM
Aug-11-22 06:22AM
Aug-04-22 10:45AM
Jun-30-22 07:33AM
Jun-20-22 07:30AM
Jun-02-22 01:00AM
May-30-22 07:06AM
May-17-22 04:05PM
May-07-22 08:27AM
May-05-22 08:55AM
May-03-22 08:15AM
Apr-20-22 08:24AM
Mar-21-22 07:30AM
Mar-15-22 06:21AM
Mar-10-22 09:43AM
Mar-08-22 07:30AM
Mar-01-22 07:30AM
Feb-17-22 07:30AM
Jan-21-22 10:21AM
Dec-23-21 07:30AM
Dec-21-21 07:30AM
Dec-16-21 07:30AM
Nov-22-21 11:46AM
Nov-15-21 06:01AM
Nov-04-21 10:15AM
Oct-28-21 03:06PM
Oct-27-21 04:50AM
Oct-14-21 06:57AM
Oct-08-21 03:35AM
Sep-22-21 07:30AM
Sep-21-21 12:33PM
Sep-20-21 07:30AM
Sep-13-21 07:30AM
Sep-07-21 01:49PM
Aug-10-21 04:35PM
Aug-05-21 08:45AM
Jul-29-21 03:05PM
Jul-28-21 07:30AM
Jul-15-21 06:38AM
Jun-23-21 03:16PM
Jun-21-21 07:30AM
Jun-08-21 10:38AM
May-21-21 08:00AM
May-06-21 09:15AM
May-03-21 07:30AM
Apr-15-21 09:05AM
Apr-12-21 07:30AM
Apr-06-21 07:02PM
Apr-05-21 04:05PM
Mar-23-21 08:00AM
Mar-22-21 07:30AM
Mar-10-21 08:45AM
Mar-03-21 05:16AM
Mar-02-21 12:30PM
Feb-23-21 04:05PM
Jan-04-21 04:05PM
Dec-30-20 05:50AM
Dec-21-20 05:00PM
Dec-10-20 11:45PM
Dec-08-20 08:38AM
Nov-16-20 07:30AM
Nov-12-20 09:47AM
Nov-11-20 07:30AM
Nov-06-20 08:56AM
Nov-05-20 09:35AM
Nov-03-20 07:30AM
Oct-28-20 07:30AM
Oct-14-20 07:30AM
Sep-23-20 12:15PM
Sep-10-20 11:18AM
Sep-02-20 07:30AM
Aug-17-20 07:19AM
Aug-06-20 07:50PM
Aug-05-20 07:30AM
Jul-28-20 12:33PM
Jul-01-20 07:30AM
Jun-29-20 07:30AM
Jun-24-20 11:00PM
Jun-22-20 01:58PM
May-11-20 01:42PM
May-05-20 09:45AM
Apr-28-20 12:39PM
Apr-27-20 12:31PM
XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BVF PARTNERS L P/ILDirectorSep 16Buy17.8924,293434,5361,773,780Sep 16 06:30 PM
BVF PARTNERS L P/ILDirectorSep 15Buy17.965,575100,1381,576,913Sep 16 06:30 PM
BVF PARTNERS L P/ILDirectorSep 14Buy17.2526,441456,0441,571,338Sep 16 06:30 PM
BURNS THOMAS M.SVP, Finance & CFOJul 15Option Exercise4.032,0008,0608,555Jul 18 04:30 PM
Neal James RCEOJul 15Option Exercise4.0325,000100,75036,822Jul 18 04:30 PM
BURNS THOMAS M.SVP, Finance & CFOJul 15Sale31.662,00063,3216,555Jul 18 04:30 PM
Neal James RCEOJul 15Sale29.8425,000746,10411,822Jul 18 04:30 PM
Neal James RCEOMar 23Option Exercise4.031,1114,47712,933Mar 23 06:52 PM
BURNS THOMAS M.SVP, Finance & CFOMar 23Option Exercise4.031616496,716Mar 23 06:52 PM
Neal James RCEOMar 23Sale30.021,11133,34811,822Mar 23 06:52 PM
BURNS THOMAS M.SVP, Finance & CFOMar 23Sale30.001614,8306,555Mar 23 06:52 PM
Neal James RCEOMar 22Option Exercise4.032,3399,42614,161Mar 23 06:52 PM
BURNS THOMAS M.SVP, Finance & CFOMar 22Option Exercise4.032,3399,4268,894Mar 23 06:52 PM
BURNS THOMAS M.SVP, Finance & CFOMar 22Sale30.022,33970,2096,555Mar 23 06:52 PM
Neal James RCEOMar 22Sale30.022,33970,20911,822Mar 23 06:52 PM
Neal James RCEOMar 21Option Exercise4.0350,000201,50061,822Mar 23 06:52 PM
BURNS THOMAS M.SVP, Finance & CFOMar 21Option Exercise4.0312,00048,36018,555Mar 23 06:52 PM
Neal James RCEOMar 21Sale29.0050,0001,450,25011,822Mar 23 06:52 PM
BURNS THOMAS M.SVP, Finance & CFOMar 21Sale29.0012,000348,0606,555Mar 23 06:52 PM